SCHEMBL25025175

SCHEMBL25025175

C[C@H]1c2c(nn(-c3ccc(F)c(C(F)(F)F)c3)c2-n2cc[nH]c2=O)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 1/20 0.34
▸ AR P10275 8/20 0.33
▸ NR1H2 P55055 1/20 0.33
▸ NR1H3 Q13133 1/20 0.33
▸ NOTUM Q6P988 1/20 0.33
▸ GPR119 Q8TDV5 2/20 0.32
▸ CRHR1 P34998 1/20 0.32
▸ GLP1R P43220 1/20 0.31
▸ RORC P51449 1/20 0.30
▸ CFTR P13569 3/20 0.30
▸ C5AR1 P21730 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21183679 0.91 GLP1R (0.36) NR1H2NR1H3GLP1R
SCHEMBL20014787 0.85 GLP1R (0.36) GLP1R
SCHEMBL26122776 0.85 GLP1R (0.36) GLP1R
SCHEMBL25025173 0.83 NOTUM (0.36) PREPARNR1H2NR1H3NOTUM
SCHEMBL20014828 0.82 GLP1R (0.33) GLP1RC5AR1
SCHEMBL38651890 0.82 GLP1R (0.35) GLP1R
SCHEMBL31692385 0.81 GLP1R (0.34) GLP1R
SCHEMBL38652284 0.81 GLP1R (0.35) GLP1R
SCHEMBL20014818 0.80 GLP1R (0.31) GLP1R
SCHEMBL21175263 0.79 GLP1R (0.38) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 — — US disclosed
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE (SHANGHAI) CO., LTD. (CN) 2023-02-21 — — US disclosed
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME ECCOGENE INC. 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584751-B1 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 PREP 742/4885AR 1010/4885NR1H2 952/4885
US-20230051320-A1 TETRAHYDROPYRAZOLO-PYRAZINYL-DIHYDROIMIDAZOLONE OR TETRAHYDROPYRAZOLO-PYRIDINYL-DIHYDROIMIDAZOLONE COMPOUNDS AND METHODS OF USING SAME GLP1R, SLC5A1, GIPR PREP 547/4885AR 1013/4885NR1H2 1105/4885
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists GLP1R, GIPR, SLC5A1 PREP 742/4885AR 1010/4885NR1H2 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback